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1. Introduction 
1.1 Adenosine and its involvement in sleep regulation 
Adenosine is a purine nucleoside structured as an adenine attached to a β-D-
ribofuranose moiety. Its derivatives are widespread in nature and some of them have 
important roles in biochemical processes, such as energy transfer as ATP and ADP or 
signal transduction as cAMP. According to current knowledge, adenosine regulates 
cellular activity by acting on four evolutionarily well-conserved metabotropic receptors:  
the purinergic G protein-coupled A1, A2A, A2B, and A3 receptors. Adenosine is not a 
neurotransmitter or a typical neuromodulator, because its formation can be increased 
by various processes in all cell types, and in all cell parts. It is well established that 
adenosine modulates sleep by acting at A1 or A2A receptors. Evidence suggests that 
A2AR suppress wakefulness to induce sleep, i.e., induce sleep gating, however, A1R 
predominantly mediate sleep need. 
1.1.1 Cellular adenosine metabolism 
Metabolism of adenosine is well studied and established (Figure 1, Zhou & Lazarus.  
Adenosinergic control of sleep/wake behavior. Handbook of Sleep Research, 2019, in 
press). Basically adenosine is formed during the hydrolysis of AMP or SAH (Fredholm, 
2007; Schrader, 1983). It can be formed from SAH by the enzyme SAH hydrolase, which 
can also act to convert adenosine when there is excess L-homocysteine. This process 
happens intracellularly and the enzyme bi-directionally maintains constant presence of a 
defined concentration of adenosine in the cell, even though the contribution of SAH 
hydrolase to the generation of adenosine in the brain seems not significant (Latini & 
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Pedata, 2001). On the other hand, adenosine can be generated both intracellularly and 
extracellularly from 5 -´AMP by 5 -´NT, mediated by a set of different enzymes 
(Zimmermann, 2000). In extracellular environment, an ecto-5 -´NT is part of a cascade 
(together with ecto-ATPases) that terminates nucleotide actions such as ATP as a 
signaling molecule (Kovacs et al., 2013; Yegutkin, 2008; Zimmermann, 2000, 2006).  
Adenosine concentrations can be controlled by the depleting enzyme ADA when they 
are high enough, and by reuptake effects (Fredholm et al., 2005; Oishi et al., 2008; 
Parkinson et al., 2011). The adenosine re-absorbed by cells is rapidly phosphorylated to 
AMP by AdK which is an enzyme that effectively regulates the intracellular adenosine 
concentration. The equilibrative nucleoside transporters can bi-directionally modulate 
the concentration of adenosine (Dos Santos-Rodrigues, Grane-Boladeras, Bicket, & Coe, 
2014; Parkinson et al., 2011). Therefore, the production and depletion of extracellular 
adenosine regulate its concentrations. In the normal baseline conditions, extracellular 
adenosine levels are low which are calculated as approximately 30 to 300 nM (Ballarin 
et al., 1991). In some special diseases or environments like mild hypoxia or strenuous 
exercise, extracellular adenosine levels can be up to 1 µM or more. Moreover, in severely 
traumatic situations, including severe local ischemia, the levels can even be several tens 
of micromolar (Fredholm, 2007).  
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Figure 1. Schematic representation of adenosine metabolism. Adenosine is produced 
by intracellular or extracellular conversion of 5'-AMP catalyzed by 5'-NT or by 
hydrolysis of SAH catalyzed by SAH hydrolase. Adenosine levels are regulated by ADA 
or adenosine kinase AdK by conversion to inosine or 5'-AMP, respectively. Equilibrative 
nucleoside transporters (ENT) bi-directionally regulate the concentration of adenosine 
available to cell surface A1, A2A, A2B, and A3 receptors (A1R, A2AR, A2BR, and A3R). 
(Modified from Zhou & Lazarus.  Adenosinergic control of sleep/wake behavior. 
Handbook of Sleep Research, 2019, in press) 
 
1.1.2 The properties of adenosine receptors 
Extracellular adenosine exerts effects when it binds on one of the four types of receptors: 
A1R, A2AR, A2BR, and A3R (Fredholm et al., 2011). A1R and A3R are coupled with 
inhibitory Gi proteins, by contrast, A2AR and A2BR are coupled with excitatory Gs 
proteins (Fredholm et al., 2005). Activation of A1R or A3R inhibits adenylate cyclase 
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activity, followed by decreased production of cAMP from ATP. This in turn down 
regulates the activity of cAMP-dependent protein kinase and cAMP response element 
binding protein phosphorylation. Therefore, Gi-coupled receptor is inhibitory to cells. In 
contrast, activation of A2AR or A2BR enhances the cAMP production and cAMP-
dependent protein kinase activity, together with cAMP response element binding protein 
phosphorylation, functioning as cell stimulation (Cunha, 2001; Fredholm et al., 2011; 
Paes-de-Carvalho, 2002). 
The receptors for adenosine are distributed throughout the whole body in mammals. A1R 
are widely distributed, which has the highest abundance in the brain despite a low-density 
expression (Daly & Padgett, 1992). Interestingly, A2AR are expressed mainly in the 
respiratory and cardiovascular system, leukocytes, and the basal ganglia of the brain 
(Fredholm et al., 2001, 2011). A2BR are expressed at low abundance throughout the body 
and A3R are differently expressed among species. For example, A3R of rats are highly 
enriched in the testis and mast cells, but in humans, A3R are mainly expressed in the lung 
and liver (Linden et al., 1993; Salvatore et al., 1993). Basal adenosine levels are able to 
activate its receptors under physiologic conditions except for the A2BR which requires a 
higher concentration (Fredholm et al., 2011). Nevertheless, the effect of adenosine at low 
concentrations also depends on the abundance of receptors. In case of only a few 
receptors, effects are possible only in a high adenosine concentration. Currently, it is 
reported that A1R and A2AR are involved in sleep regulation but the other two are not 
(Lazarus et al., 2017).
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1.1.3 Associations between adenosine levels and sleep 
Adenosine was initially isolated for the first time from cardiac tissue extracts in 
1929.More than 60 years have passed since the discovery of its hypnotic effect in the cat 
brain in 1954 (Drury & Szent-Gyorgyi, 1929; Feldberg & Sherwood, 1954). Similar 
somnogenic effects of adenosine were subsequently observed in a dogs, fowls, rats, and 
mice (Dunwiddie et al., 1982; Haulica et al., 1973; Marley et al., 1972; Radulovacki et 
al., 1984, 1985; Ticho et al., 1991). However, how adenosine regulates sleep, i.e, the 
brain cell types involved in the adenosinergic sleep-inducing effects, and the relative 
contributions of A1R and A2AR to sleep/wake regulation remain unclear. 
 There is a hypothesis that adenosine actually stands for a state of relative energy 
deficiency. Therefore, early concepts of sleep/wake regulation assumed that the desire 
for sleep periodically is to replenish low energy stores, at least partially if not all. (Pull 
& Mcilwain, 1972; Tobler & Scherschlicht, 1990; Vanwylen et al., 1986). Actually, in-
vivo microdialysis assays of extracellular adenosine levels in the hippocampus and 
neostriatum in freely-behaving rats revealed that adenosine levels are higher during the 
inactive period than the active period, which seems to be a strong support to this theory 
(Huston et al., 1996). Additionally, it is also hypothesized that extracellular adenosine 
levels allow the brain to assess the need for sleep. The discovery in rats suggests that 
systemic or intracerebroventricular administration of CPA, a selective A1R agonist, dose-
dependently increases SWA during sleep, similar to the response to sleep deprivation. 
SWA is a slow oscillatory neocortical activity (usually defined from 0.5 to 4.0 Hz) that 
is increased following prolonged wakefulness but descends during sleep thus it is 
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considered as a marker of sleep homeostasis, in other words, a balance between waking 
and sleep (Benington et al., 1995).  
ATP depletion is positively correlated with an increase in extracellular adenosine levels 
(Kalinchuk et al., 2003) and sleep (Porkka-Heiskanen et al., 1997). Adenosine levels 
measured by in-vivo microdialysis from several brain areas in cats during spontaneous 
sleep-wake cycles were higher during sleep than wakefulness (Porkka-Heiskanen et al., 
1997, 2000). These experiments also revealed a 2-fold increase in adenosine levels in the 
BF during a prolonged 6h wakefulness compared with levels at the beginning of sleep 
deprivation (Porkka-Heiskanen et al., 1997, 2000). Therefore, adenosine is thought to 
control BF neurons via A1R since A1R mRNA is significantly increased in the BF after 
sleep deprivation. Besides, perfusion of adenosine or the A1R agonist 
cyclohexyladenosine into the BF induces sleep by inhibiting wake-active neurons, 
whereas the A1R antagonist CPT induces wakefulness (Basheer et al., 2000, 2001).  
Furthermore, pharmacological studies found that inhibition of ADA, AdK, and 
equilibrative nucleoside transporters leads to sleep due to increased extracellular 
adenosine levels (Oishi et al., 2008; Okada et al., 2003; Porkka-Heiskanen et al., 1997; 
Radulovacki et al., 1983). These results established a strong correlation between 
adenosine metabolism and sleep. 
 
1.2 The Nucleus accumbens and its role in sleep regulation 
1.2.1 The anatomical properties of the NAc 
The NAc is a nucleus located in the ventral striatum (Figure 2), containing core and 
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shell subunits which are composed of GABAergic projection neurons (about 95% 
MSNs and 1~2% interneurons) and cholinergic interneurons (about 1~2%) (George 
Paxinos & Keith Franklin, 2001; Robison & Nestler, 2011). Basically, the MSNs in the 
NAc can also be sorted into direct and indirect pathway neurons which can be 
distinguished by the expression of dopamine D1R or D2R respectively. The two kinds 
of heterogeneous MSNs play complementary but sometimes opposite roles in 
modulating brain functions and behaviors. Moreover, the MSNs of the direct pathway 
co-express the excitatory D1R and inhibitory adenosine A1R. In contrast, the indirect 
pathway neurons co-express inhibitory D2R and the excitatory adenosine A2AR (Lee et 
al., 2016; Nam et al., 2013). The NAc primarily is regulated by several typical 
neurotransmitters such as glutamate, dopamine and histamine from other brain regions 
(Blum et al., 2012; Gipson et al., 2014; Goto & O'Donnell, 2001; Malenka et al., 2009; 
Robison & Nestler, 2011). Glutamatergic inputs from the Amyg, mPFC and vHipp are 
considered the most robust sources of input to the NAc (Britt et al., 2012), while input 
from the PVT and VTA were also reported (Ren et al., 2018; Yu et al., 2019). It is well 
established that the NAc plays a pivotal role in mesolimbic dopamine regulation, in 
which the dopaminergic neurons in the VTA and medial SNc are usually taken as the 
major dopaminergic inputs (Brog et al., 1993; Joel & Weiner, 2000; Lynd-Balta & 
Haber, 1994; Swanson, 1982). Additionally, the TMN is the sole source of histamine in 
human and mouse brains, and, the NAc is one of the few regions that receive its 
histaminergic regulation (Haas & Panula, 2003; Inagaki et al., 1988; Swanson, 1982; 
Wada et al., 1991). Projection output from the NAc is widespread. Tracing by 
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immunohistochemistry and electron microscopy revealed that the D1R/A1R direct 
pathway neurons mainly project to the midbrain and lateral hypothalamus (Luo et al., 
2018). Similarly, the D2R/A2AR indirect pathway neurons mainly send termini to the 
BF, lateral hypothalamus and midbrain (Zhang et al., 2013). 
 
Figure 2. Scheme of anatomical representation of the NAc in the brain. a A typical 
sagittal representative section of the NAc in the brain. b The coronal section part of Fig 
2a. Red dash lines and characters represent the NAc core and the dark blue characters 
indicates the NAc shell. (Modified from George Paxinos, & Keith Franklin. (2001). The 
Mouse Brain in Stereotaxic Coordinates. 2nd edn. Academic Press.).  
 
1.2.2 The NAc plays an important role in sleep/wake regulation 
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Previous studies revealed an important role of the NAc MSNs in regulating both sleep 
and arousal. Caffeine, as the most consumed psychoactive substances in the world every 
day, exerts its strong arousal effect via A2AR in the NAc shell in mice (Huang et al., 
2005; Lazarus et al., 2011). Bilateral nonspecific-neurotoxic lesion of the NAc core or 
shell by microinjected 1% ibotenic acid resulted in increased wakefulness in rats (Qiu 
et al., 2012). Besides, in-vivo electrophysiological recordings in the NAc discovered a 
decreased firing rate of numerous neurons during SWS in rats (Tellez et al., 2012). 
Further study revealed that opto- and chemogenetic activation of D1R direct pathway 
neurons can induce fast transitions from SWA to arousal and prolonged wakefulness, 
indicating that D1R/A1R positive neurons in the NAc play an important role in arousal 
onset and maintenance (Luo et al., 2018). Moreover, Oishi and colleagues uncovered a 
prominent role of A2AR expressing neurons in the NAc in sleep/wake regulation and 
proposed a novel brain circuit (NAc core - VP) for sleep control by motivated behavior 
(Oishi et al., 2017). Activation of the indirect pathway D2R/A2AR expressing neurons 
in the NAc core robustly induces sleep, however, inhibition of these neurons decreases 
sleep baseline without disturbing sleep homeostasis, indicating a necessity of these 
neurons in sleep. Besides, motivational stimuli inhibit the activity of the VP-projecting 
NAc A2AR expressing neurons and suppress sleep (Oishi et al., 2017). This brain circuit 
may explain the tendency to fall asleep in the absence of motivating stimuli, i.e., when 
bored. However, how these sleep-promoting D2R/A2AR expressing neurons are 
activated in-vivo is still unknown. Adenosine is an obvious candidate molecule that 
activates NAc A2AR-expressing neurons because sufficient levels of adenosine are 
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available under basal conditions and bind to excitatory A2AR. The source of the 
adenosine, however, remains obscure. 
 
1.3 Astrocyte, a promising source of extracellular adenosine 
Astrocytes, also known as astroglia, are a kind of glia cells distributed throughout the 
brain and spinal cord (the other kinds of glia cells are microglia and oligodendrocyte). 
This kind of star-shaped cell constructs the biggest cell population in the brain, 
outnumbering neurons five-fold (Sofroniew & Vinters, 2010). Astrocytes are well 
known for many classical functions like structural support (forming blood vessels and 
the BBB), balancing extracellular concentration of ions and neurotransmitters, nutrition 
delivery, synaptic transmission modulation, and so on (Brooks, 2009; Sofroniew & 
Vinters, 2010). A protein named as GFAP expressed by astrocytes plays an essential 
role in exerting their functions especially when they are activated and form into 
astrogliosis (Pekny et al., 1995; Pekny & Pekna, 2004; Sofroniew, 2009). It is well 
known that GFAP is a typical and specific astroglial marker since, generally, neurons 
and other glia do not express this protein. However, only a fraction of astrocytes (~20% 
to 40%) express detectable GFAP mRNA in basal condition (Sofroniew, 2009; 
Sofroniew & Vinters, 2010). This made GFAP a reliable marker in labelling reactivated 
astrocytes but notorious in labelling basal ones, compared to the other specific astroglial 
markers, for example, S100β.  
For a long time, astrocytes were taken for granted as inert participants in regulating 
behavioral functions since they are “silent”, i.e., they cannot fire like neurons. But with 
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developing knowledge and neurobiological techniques, a number of novel functions of 
astrocytes, especially involvement in sleep regulation, are starting to emerge. It is well 
established that adenosine (and ATP, which is rapidly degraded into adenosine) can be 
released in the brain from neurons and glia cells. Genetically engineered mice in which 
a dnSNARE domain is selectively expressed in astrocytes to non-specifically block the 
release of ATP exhibit decreased levels of extracellular adenosine (Chen & Scheller, 
2001; Pascual et al., 2005; Raingo et al., 2012). Although in these mice, the amount of 
wakefulness, SWS and REM sleep are indistinguishable from that in wild-type mice, 
they exhibit reduced SWA and recovery sleep after sleep deprivation (Halassa et al., 
2009), suggesting that adenosine released from astrocytes is involved in an 
accumulation of sleep pressure. Direct proof is still lacking, however, and thus the exact 
sources of adenosine remain unknown. Work by Greene and colleagues provides 
evidence for adenosine-mediated regulation of the homeostatic sleep need via 
activation of neuronal A1R controlled by glial AdK (Bjorness et al., 2009, 2016). As a 
matter of fact, mice deficient in glial AdK exhibit increased SWA rebound and 
consolidation, and an increased time constant of SWA during an average sleep episode. 
These findings implicate astrocytes as a promising source of adenosine in sleep 
regulation; however, the role of NAc astrocytes in sleep regulation is not known. 
 
1.4 Diphtheria toxin and its novel applications in research 
Diphtheria toxin is an exotoxin secreted by corynebacterium diphtheria, which is 
famous for causing the severe disease “diphtheria” after infection. It consists of two 
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fragments: fragment A and B. When the diphtheria toxin contacts a cell expressing its 
receptor, fragment B binds to it followed by penetration through the cellar membrane 
(Bell & Eisenberg, 1996; Mitamura et al., 1995). Fragment A is cleaved and released 
after reaching the cytosol of the victim cell and soon kills the cell by inhibiting a subunit 
ADP-ribosylates host EF-2 which is required for protein synthesis (Honjo et al., 1968; 
Kimata & Kohno, 1994; Kohno et al., 1986; Kohno & Uchida, 1987; Robinson et al., 
1974; Van Ness et al., 1980). Diphtheria toxin fragment A is extremely toxic. A cell can 
be killed by even just one molecule of DTA in the cytosol (Yamaizumi et al., 1978). 
Humans and monkeys are highly susceptible to the diphtheria toxin, however, mice and 
rats are resistant. A comparative study showed that the native DTR of rodents lacks a 
transport process, thus explaining the lower efficiency of the toxin compared to humans 
or monkeys (Chang & Neville, 1978).  
The diphtheria toxin fragment A is widely used in cell ablation studies. Cytotoxic DTA 
genes are usually specifically expressed in the ablation target cells directly by classic 
AAV vector or transgenic mice, especially Cre-recombinase dependent mice created by 
the CRISPR-Cas9 genome editing method (Brockschnieder et al., 2004; Kohlschutter 
et al., 2010; Palmiter et al., 1987). However, there is a conspicuous deficiency of these 
tools in which the ablation of cells immediately starts after DTA expression. Thus it is 
impossible to measure baseline parameters. For example, in neurobiological 
experiments, mice usually need several days to recover from the injuries caused by 
virus injection. However, cell ablation starts from the moment of infection, which 
makes it impossible to assess accurate baseline parameters during recovery. Therefore, 
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to solve this issue, specific expression of DTR (usually from monkey) in mice were 
established (Iwasaki et al., 2018; Saito et al., 2001).  
 
2. The aim of this study 
In this study, we aimed to ablate GFAP positive cells in the NAc to investigate if there 
is any change in sleep/wake cycle, using virus-mediated expression of DTR and 
intraperitoneal administration of DT. Meanwhile immunohistochemical and 
neurochemical investigations related to the behavioral study were also performed. 
 
3. Materials and methods 
3.1 Animals  
A mouse strain expressing EYFP in mouse GFAP-positive cells (lox-stop-lox-
EYFP/mGFAP-Cre) was established by crossing R26-stop-EYFP mice (Jackson 
Laboratory, strain number 007903) (Srinivas et al., 2001) with mGFAP-Cre mice 
(Garcia et al., 2004). In addition, a global A2AR knockout mouse line was used (Chen 
et al., 1999). All mice (weighing 20–35 g, 8–24 weeks old) used in the present study 
were housed at a constant temperature of 23 ± 1°C with a relative humidity of 60 ± 2% 
in an automatically controlled 12-h light/dark cycle (lights on at 7:00, off at 19:00), and 
provided with water and food ad libitum. All experiments were performed in 
accordance with the Animal Care Committee of the University of Tsukuba and the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals, and 
every effort was made to minimize the number of animals used, as well as any pain and 
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discomfort. 
 
3.2 Plasmids and AAV generation 
To generate the pAAV-GFAP-DTR-P2A-mCherry plasmid, the hM4D(Gi) fragment in 
pAAV-GFAP-hM4D(Gi)-mCherry, kindly provided by Dr. Bryan Roth (University of 
North Carolina; Addgene plasmid #50479), was replaced with a PCR-amplified 
fragment containing the DTR-P2A coding sequence using restriction cloning.  
The AAV serotypes of shH10 for recombinant AAV-GFAP-DTR-mCherry and AAV-
GFAP-mCherry were generated as described previously (Zolotukhin et al., 1999). In 
brief, the AAVs were generated by tripartite transfection into 293A cells. After 3 days, 
the 293A cells were resuspended in artificial cerebrospinal fluid, freeze-thawed four 
times, and treated with Benzonase® nuclease (Millipore, Burlington, MA) to degrade 
all forms of DNA and RNA. Subsequently, the cell debris was removed by 
centrifugation and the virus titer in the supernatant was determined using an AAVpro 
Titration Kit for Real Time PCR (Takara Bio, Kusatsu, Japan). 
 
3.3 Stereotaxic AAV injection, EEG/EMG recordings and vigilance 
state assessment 
Surgeries for brain microinjections were conducted under pentobarbital anesthesia 
(60 mg/kg, i.p.). Using aseptic techniques, the mice were stereotaxically and bilaterally 
injected into the NAc with recombinant AAV-GFAP-DTR-mCherry (264 nl/side, 
1× 1011 particles ml−1) or AAV-GFAP-mCherry (264 nl/side, 9× 1010 particles ml−1) 
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with a glass micropipette and an air pressure injector system (Chamberlin et al., 1998). 
The following coordinates were used according to the mouse brain atlas of Paxinos and 
Franklin (2001): AP + 1.5 mm; ML ± 1.2 mm; DV –4.1 mm.  
Mice were chronically implanted with EEG and EMG electrodes for polysomnography, 
as previously described (Oishi et al., 2016). Briefly, the implant contained two stainless-
steel screws (1 mm diameter) serving as EEG electrodes, one of which was placed 
epidurally over the right frontal cortex (1.0 mm anterior and 1.5 mm lateral to bregma) 
and the other over the right parietal cortex (1.0 mm anterior and 1.5 mm lateral to 
lambda). Two insulated Teflon-coated, silver wires (0.2 mm in diameter), which were 
placed bilaterally into the trapezius muscles, served as EMG electrodes. Both EEG and 
EMG electrodes were connected to a microconnector, and the whole assembly was then 
fixed to the skull with self-curing dental acrylic resin. 
After recovering for at least 3 weeks, the mice were connected to an EEG/EMG 
recording cable in a soundproof recording chamber and habituated for at least 3 days 
before any polysomnographic recording (Figure 3a, b, c). The EEG/EMG signals were 
amplified, filtered (EEG, 0.5–30 Hz; EMG, 20–200 Hz), digitized at a sampling rate of 
128 Hz, and recorded using SLEEPSIGN software ver. 3 (Kissei Comtec, Matsumoto, 
Japan) (Kohtoh et al., 2008). 
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Figure 3. Schematic diagram of the polysomnographic recording system in 
Lazarus lab in IIIS. a Schematic representation of the polysomnographic recording 
system. b Computers and video monitors used for sleep recording. c A mouse 
undergoing recording in the recording chamber. 
 
EEG/EMG data visualized by the analysis software were calculated in 10-s epochs and 
three stages were recognized based on their spectrum and wave properties (Oishi et al., 
2016): SWS, rapid eye movement (REM) sleep, and wakefulness (Fig 4). SWS is 
recognized by low-frequency, synchronized high-amplitude and spindle-like EEG, 
silenced EMG and a high percentage of delta power (0.5-4.0 Hz) (Fig 4). In contrast, 
wakefulness is distinguished by high-frequency but low amplitude and desynchronized 
EEG and active EMG (Fig 4). REM sleep EEG looks like wakefulness but with almost 
silenced EMG and a remarkably high theta power (Fig 4). Percent change of slow-wave 
activity was also calculated based on the SWS delta power (0.5–4 Hz) during 24 h and 
normalized to the baseline condition.  
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Figure 4. The characterizations of vigilance stages： SWS, REM sleep and 
wakefulness.  
 
3.4 Microdialysis in freely behaving mice and measurement of 
adenosine by HPLC 
Under pentobarbital anesthesia (60 mg/kg, i.p.), mice were bilaterally implanted with 
guide cannulas (inner diameter 0.40 mm, outer diameter 0.50 mm; Eicom, Kyoto, Japan) 
into the brain using the following coordinates according to the mouse brain atlas of 
Paxinos and Franklin (2001): AP +1.4 mm; ML ±1.2 mm; DV −2.9 mm. Two stainless-
steel screws (1 mm diameter) were also implanted to stabilize the guide cannulas, and 
then dummy cannulas (diameter 0.37 mm, Eicom) were inserted to prevent the guide 
cannula from clogging. After recovering for at least 3 weeks, the mice were transferred 
to the recording chambers for habituation. On the sampling day, each mouse was 
quickly anesthetized using isoflurane and the dummy cannula was removed followed 
by insertion of the microdialysis probe (1 mm membrane length, 8.4% adenosine 
recovery rate; Eicom) into the guide cannula. The probe was infused continuously using 
an infusion pump with Ringer’s solution (147 mM NaCl, 4 mM KCl, and 2.4 mM CaCl2) 
at a flow rate of 0.5 μl/min (Figure 5a). Two hours after inserting the probe, dialysates 
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were continuously collected from the probe for 3 h (Figure 5a). The dialysates were 
kept at −20°C until adenosine was measured by HPLC (Figure 5b). A TSKgel®ODS-
100V HPLC column (Tosoh Bioscience, Tokyo, Japan) together with a mobile phase 
comprising 100 mM NaH2PO4 and acetonitrile in a ratio of 96:4 at a flow rate of 1 
ml/min was used for HPLC separation, and 80 μl of each dialysate was injected into a 
HPLC-LabSolutions LC system (Shimadzu, Kyoto, Japan) equipped with a UV (260 
nm) detection system. External adenosine standards were used to determine the 
retention time and to calculate the adenosine concentrations in the dialysates by the 
HPLC software (Figure 5c).  
 
Figure 5. Schematic representations of the adenosine assay system. a Schematic 
representation of microdialysis in freely moving mice. b Shimadu-LabSolution HPLC 
system used in this study in the IIIS. c A typical chromatograph of a dialysate sample 
analyzed by the HPLC system. 
 
3.5 Histology 
Under deep chloral hydrate (500 mg/kg, i.p.) anesthesia, the mice were perfused via the 
heart with saline followed by a 10% formalin solution. The brains were removed and 
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immersed in the same fixative overnight at 4°C and then transferred into a 20% sucrose 
solution.  
For immunohistochemistry, the brains were then frozen on dry ice and sectioned at 
40 µm on a freezing microtome (Thermo Fisher Scientific, Waltham, MA). 
Immunohistochemistry was performed on free-floating sections as described previously 
(Lazarus et al., 2011). In brief, the sections were rinsed in PBS, incubated in 0.3% 
hydrogen peroxide in PBS for 30 min at room temperature, and then sequentially 
incubated at room temperature in 3% normal donkey serum and 0.25% Triton X-100 in 
PBS (PBT) for 1 h and then overnight in primary antibody diluted in PBT with 0.02% 
sodium azide. After overnight incubation with rabbit anti-DsRed antibody (1:5000; 
Cat# 632496, Takara Bio), the sections were rinsed and incubated for 2 h in biotinylated 
antibody (Jackson ImmunoResearch Lab, West Grove, PA) at a dilution of 1:1000. All 
tissue sections were then treated with avidin-biotin complex (1:1000; Vectastain ABC 
Elite kit, Vector Labs, Burlingame, CA) for 1 h, and immunoreactive cells were 
visualized by reaction with 3,3′-diaminobenzidine and 0.01% hydrogen peroxide. 
Tissue sections mounted on glass slides were scanned with a Hamamatsu NanoZoomer-
XR Digital slide scanner (Hamamatsu Photonics, Hamamatsu, Japan), and digital 
photomicrographs were analyzed using Hamamatsu NDPView software v2.4.26. 
For fluorescent double-labeling, the sections were rinsed in PBT and incubated in PBT 
containing 10% BlockAce (DS PharmaBiomedical, Osaka, Japan) for 30 min at room 
temperature. The sections were then incubated with the rabbit anti-GFAP antibody 
(1:200, Cat# HPA056030, Sigma-Aldrich, St. Louis, MO), goat anti-mCherry antibody 
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(1:1000, Cat# AB0040-200, SICGEN, Cantanhede, Portugal), mouse anti-NeuN 
antibody (1:100, Cat# MAB377, Millipore), rabbit anti-S100β (1:100, Cat# 
HPA015768, Sigma-Aldrich, St. Louis, MO) or rabbit anti-TMEM119 antibody (1:200, 
Cat# ab209064, Abcam, Cambridge, UK) containing 5% BlockAce at room 
temperature in the combinations described in the Results section. After overnight 
incubation, the sections were rinsed in PBT and incubated with donkey anti-goat Alexa 
Fluor® 594 nm (1:1000, Thermo Fisher Scientific), donkey anti-mouse Alexa Fluor® 
647 nm (1:500, Thermo Fisher Scientific), or donkey anti-rabbit Alexa Fluor® 647 nm 
(1:500, Thermo Fisher Scientific) containing 5% BlockAce for at least 2 h. The sections 
were then mounted on glass slides and sealed with mounting medium containing DAPI 
dye (Vector Labs, Cat# H-1200) and cover glass. Fluorescence signals were visualized 
using an LSM 700 confocal microscope (Zeiss, Oberkochen, Germany). 
For quantitative histologic analysis, pictures of tissues containing the NAc at the same 
bregma level were obtained using a confocal microscope in the Z stack mode. In Fig. 
6b, a 0.35 mm x 0.35 mm area in the NAc of each tissue was analyzed. The percentage 
of NeuN/mCherry and S100β/mCherry-positive cells among mCherry/DAPI-positive 
cells was calculated. In Fig. 8g, the number of GFAP/DAPI-positive cells was counted 
in and normalized to the AAV area. The AAV area (i.e., the area showing mCherry 
expression) was measured using ImageJ software. 
 
3.6 Statistical analysis 
Data are presented as mean ± standard error of the mean (SEM) and were analyzed 
using SPSS statistics 25 (IBM, Armonk, NY). One-way ANOVA followed by the 
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Fisher’s Protected Least Significant Difference test or two-way ANOVA followed by 
the PLSD test was performed for all the statistical analysis. In all cases, a p-value less 
than 0.05 was considered significant. 
 
4. Results 
4.1 SWS increased after cytotoxic ablation of NAc GFAP-positive cells. 
To examine the role of NAc astrocytes in sleep–wake regulation, we ablated GFAP-
positive cells in the NAc core of mice by stereotaxic microinjection of AAV carrying 
DTR under a GFAP promoter (AAV-GFAP-DTR, Fig. 6a) and i.p. injection of DT 
(Wako, Japan) 3 weeks after microinjection. AAV-GFAP-DTR was injected in lox-stop-
lox-EYFP/mGFAP-Cre mice, denoted as A2AR
WT mice, or A2AR knockout mice 
(A2AR
KO mice). 
First, we evaluated the specificity of DTR expression in AAV-GFAP-DTR-injected 
A2AR
WT mice by immunohistochemical investigation of the expression of the neuronal 
marker NeuN, the astrocytic marker S100β and the AAV-reporter protein mCherry (Fig. 
6b). We detected 21.4% ± 3.5% of NeuN/mCherry-positive cells and 73.0% ± 5.8% of 
S100β/mCherry-positive cells among all mCherry-positive cells across six NAc-
containing brain sections from three mice in each group, suggesting that most infected 
cells were astrocytes but a minority were neurons.  
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Figure 6. Adeno-associated virus-mediated expression of diphtheria toxin receptors. a 
Construct for multi-gene expression of DTR and mCherry via 2A self-cleaving peptide 
driven by the GFAP-promoter. b DTR is expressed in astrocytes and a small number of 
neurons after AAV infection as revealed by immunohistochemical staining with 
antibodies against the neuronal marker NeuN, astrocytic marker S100β and AAV 
reporter protein mCherry. White arrows indicate NeuN/mCherry-positive (top right 
panel) or S100β/mCherry-positive (bottom right panel) cells. Scale bar: 40 μm. 
 
Next, we stereotaxically microinjected AAV-GFAP-DTR bilaterally into the NAc core 
of A2AR
WT mice, denoted as A2AR
WT NAc GFAP-DTR mice, and as controls, we 
injected AAV-GFAP-mCherry into the NAc core of A2AR
WT mice (A2AR
WT NAc GFAP-
mCherry mice; Fig. 7a, b). Three weeks after the AAV injections, EEG and EMG 
recordings of the mice were analyzed to assess the baseline sleep/wake behavior of the 
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animals. Initially, only A2AR
WT NAc GFAP-DTR mice were treated with DT (50 μg/kg, 
i.p.), and EEG and EMG recordings were obtained on days 9 to 14 following the 
treatment. We analyzed SWS amounts in A2AR
WT NAc GFAP-DTR mice during dark 
and light periods compared with the baseline. We found that SWS was significantly 
increased in the dark and light periods of day 9 and then gradually returned to the 
baseline level until day 14 (Fig. 7c). Therefore, we next obtained EEG and EMG 
recordings of A2AR
WT NAc GFAP-DTR and NAc GFAP-mCherry mice for 9 days after 
DT treatment. SWS increased in the A2AR
WT NAc GFAP-DTR mice during the dark 
period from day 5 after DT treatment before reaching a maximum on day 7 after DT 
treatment, compared with DT-treated control mice (day 5: F(1, 9)=7.808, p=0.011; day 
6: F(1, 9)=6.470, p=0.024; day 7: F(1, 9)=21.858, p=0.0001; day 8: F(1, 9)=6.907, p=0.026; 
day 9: F(1, 9)=8.050, p=0.023; Fig. 7d). SWS also increased significantly in the A2AR
WT 
NAc GFAP-DTR mice during the light period between days 1 and 8, compared to the 
DT-treated control mice (day 1: F(1, 9)= 3.948, p=0.015; day 2: F(1, 9)=7.591, p=0.002; 
day 3: F(1, 9)=3.205, p=0.024; day 4: F(1, 9)=2.971, p=0.031; day 5: F(1, 9)=4.316, 
p=0.012; day 6: F(1, 9)=4.379, p=0.021; day 7: F(1, 9)=8.384, p=0.011; day 8: F(1, 
9)=6.679, p=0.013; Fig. 7d). We also stereotaxically microinjected AAV-GFAP-DTR 
bilaterally into the NAc core of A2AR
KO mice, denoted as A2AR
KO NAc GFAP-DTR 
mice, and as controls, we injected AAV-GFAP-mCherry into the NAc core of A2AR
KO 
mice (A2AR
KO NAc GFAP-mCherry mice; Fig. 7a). SWS was not increased in DT-
treated A2AR
KO NAc GFAP-DTR mice, however, compared with A2AR
KO NAc GFAP-
mCherry mice in either the dark or light periods (Fig. 7e). This observation suggests 
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that the SWS increase after DT treatment is mediated by adenosine via A2AR.  
On day 7, when the mice had the strongest SWS increase, A2AR
WT NAc GFAP-DTR 
mice exhibited increased SWS and REM sleep, especially during the dark period, 
compared with DT-treated control mice (Fig. 7f, g). Concomitantly, A2AR
WT NAc 
GFAP-DTR mice had a lower amount of wakefulness. By contrast, we did not observe 
notable changes in the hourly SWS and REM sleep amounts of A2AR
KO NAc GFAP-
DTR mice on day 7 after DT treatment, compared with A2AR
KO NAc GFAP-mCherry 
mice (Fig. 7h, i). The increased amount of SWS in A2AR
WT NAc GFAP-DTR mice 
during the dark period of day 7 after DT treatment was due to an increased number of 
SWS episodes, while the mean duration of SWS episodes was not changed (Fig. 7j, k). 
A change in SWA is considered a hallmark of sleep homeostasis disturbance (Dispersyn 
et al., 2017; Wang et al., 2018). To investigate whether sleep homeostasis was affected 
by cytotoxic ablation of NAc GFAP-positive cells, we calculated changes in SWA on 
day 7 normalized to the baseline; however, there was no significant difference in the 
normalized SWA in all the mouse groups (Fig. 7l, m). 
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Figure 7. SWS is increased after cytotoxic ablation of GFAP-positive cells in the NAc 
core in A2AR
WT but not in A2AR
KO NAc GFAP-DTR mice. a AAV-GFAP-DTR was 
bilaterally microinjected into lox-stop-lox-EYFP/mGFAP-Cre (A2AR
WT) or A2AR
KO 
mice. b Typical AAV infection in the NAc core as indicated by mCherry expression. 
Scale bar: 200 μm. c SWS during the dark and light periods 1 day before and at 9 to 14 
days after DT treatment in A2AR
WT NAc GFAP-DTR mice (n=4). **p <0.01 vs baseline 
day (i.e., day before DT treatment), assessed by one-way ANOVA. d SWS during the 
dark and light periods 1 day before and for 9 days after DT treatment in A2AR
WT NAc 
GFAP-mCherry (n=5) and NAc GFAP-DTR (n=6) mice. *p <0.05, **p <0.01 vs 
A2AR
WT NAc GFAP-mCherry mice; assessed by one-way ANOVA. e SWS during the 
dark and light periods 1 day before and for 9 days after DT treatment in A2AR
KO NAc 
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GFAP-mCherry (n=4) and NAc GFAP-DTR (n=6) mice. f-i SWS (f, h), and REM-
sleep (g, i) time-courses of all the mouse groups on day 7 after DT treatment. *p <0.05, 
**p <0.01 vs A2AR
WT NAc GFAP-mCherry (f, g) or A2AR
KO NAc GFAP-mCherry (h, 
i) mice; assessed by two-way ANOVA followed by the PLSD test. j, k Mean duration 
(j) and number (k) of SWS episodes during the dark and light periods on day 7 after 
DT treatment in A2AR
WT NAc GFAP-mCherry (n=5) and A2AR
WT NAc GFAP-DTR 
(n=6) mice. *p < 0.05 vs A2AR
WT NAc GFAP-mCherry mice, assessed by one-way 
ANOVA. l, m SWS-SWA time-courses of all the mouse groups on day 7 after DT 
treatment. *p <0.05, **p <0.01 vs A2AR
KO NAc GFAP-mCherry mice; assessed by two-
way ANOVA followed by the PLSD test. 
 
4.2 Cytotoxic ablation of NAc GFAP-positive cells led to increased 
activation of astrocytes and microglia  
We then evaluated the effects of cytotoxic ablation of GFAP-positive cells in the NAc 
after DT treatment by immunohistochemical investigation of the expression of the 
astrocyte-reporter protein EYFP and the AAV-reporter protein mCherry (Fig. 8a-c). No 
EYFP- and mCherry-positive cells were observed in A2AR
WT NAc GFAP-DTR mice 
after DT treatment (Fig. 8a), whereas many double-positive cells were observed in 
A2AR
WT NAc GFAP-DTR mice treated with saline or A2AR
WT NAc GFAP-mCherry 
mice treated with DT (Fig. 8b, c). These findings suggest that cells infected with AAV-
GFAP-DTR were completely ablated by the administration of DT.  
Next, we examined the residual NAc astrocytes on day 7 after DT administration by 
immunohistochemical investigation of the expression of the endogenous astrocyte 
marker GFAP and the AAV-reporter protein mCherry (Fig. 8d-f). Surprisingly, GFAP 
expression was remarkably increased in A2AR
WT NAc GFAP-DTR mice treated with 
DT compared with A2AR
WT NAc GFAP-DTR mice treated with saline or A2AR
WT NAc 
GFAP-mCherry mice treated with DT. The number of GFAP-expressing cells within 
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the AAV infection area, as indicated by the mCherry expression, was significantly 
higher than that in the control mice (F(2, 14)=10.380, p=0.008, A2AR
WT NAc GFAP-
DTR/DT vs A2AR
WT NAc GFAP-DTR/saline; F(2, 14)=10.380, p=0.001, A2AR
WT NAc 
GFAP-DTR/DT vs A2AR
WT NAc GFAP-mCherry/DT, Fig. 8g).  
Because we observed an unexpected increase in GFAP expression after cytotoxic 
ablation of NAc GFAP-positive cells, we also examined the morphology of microglia 
in A2AR
WT NAc GFAP-DTR mice by immunohistochemical analysis with an antibody 
against the microglia marker TMEM119 (Fig. 8h, i). Activated microglia were detected 
in DT-treated A2AR
WT NAc GFAP-DTR mice (Fig. 8i), but not in DT-treated A2AR
WT 
NAc GFAP-mCherry mice. This observation suggests DT-mediated apoptosis of GFAP 
cells in the NAc is accompanied by microglia activation. 
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Figure 8. The number of GFAP-expressing cells is increased and microglia are 
activated after cytotoxic ablation of NAc GFAP-positive cells. a-c AAV-infected cells 
are destroyed in DT-treated A2AR
WT NAc GFAP-DTR mice (a) but not in saline-treated 
A2AR
WT NAc GFAP-DTR (b) or DT-treated A2AR
WT NAc GFAP-mCherry mice (c) on 
day 7 after DT injection. White arrows indicate AAV-infected astrocytes. Scale bars: 50 
μm. d-f Increased number of GFAP-positive cells in DT-treated A2ARWT NAc GFAP-
DTR (d) compared with saline-treated A2AR
WT NAc GFAP-DTR (e) or DT-treated 
A2AR
WT NAc GFAP-mCherry mice (f). Scale bars: 50 μm. Red dashed lines indicate 
area with mCherry expression. g Number of GFAP-positive cells (astrocytes) in the 
AAV-infected area on day 7 after DT treatment in A2AR
WT NAc GFAP-DTR/DT (n=6), 
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A2AR
WT NAc GFAP-DTR/saline (n=5) and A2AR
WT NAc GFAP-mCherry/DT (n=6) 
mice. Significance was assessed by one-way ANOVA followed by the PLSD test. h, i 
Immunostaining of activated or ramified microglia in A2AR
WT NAc GFAP-DTR (h) or 
A2AR
WT NAc GFAP-mCherry mice (i), respectively, after DT treatment. White arrows 
indicate activated/phagocytic microglia in the NAc. Scale bars: 40 μm. 
 
4.3 Extracellular adenosine levels increased after ablation of NAc 
GFAP-positive cells 
Finally, we investigated extracellular adenosine levels on day 7 after DT treatment using 
microdialysis (Fig. 9a, b). The dialysates were collected between 19:00 and 22:00 when 
there is a large increase in SWS and analyzed by HPLC. Dialysates were collected 
before and after DT treatment by inserting the same probe in contralateral sites of the 
mouse brain. The adenosine concentration was determined by comparison with 
adenosine standards (Fig. 9c) and normalized between the samples taken before and 
after DT treatment due to the varying recovery rates of the microdialysis probes. The 
position of the microdialysis probe was confirmed by immunohistochemical analysis 
of the expression of the AAV reporter protein mCherry (Fig. 9d). 
Adenosine levels increased significantly after DT administration in A2AR
WT and 
A2AR
KO NAc GFAP-DTR mice, compared with A2AR
WT NAc GFAP-mCherry mice 
(A2AR
WT NAc GFAP-mCherry vs A2AR
WT NAc GFAP-DTR, F(2, 10)= 4.486, p=0.037; 
A2AR
WT NAc GFAP-mCherry vs A2AR
KO NAc GFAP-DTR, F(2, 10)= 4.486, p=0.019; 
Fig. 9e). These findings suggest that ablation of GFAP-positive cells in the NAc results 
in an increase in extracellular adenosine, at least on day 7 after cell apoptosis is initiated 
by DT treatment.  
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Figure 9. Measurement of extracellular adenosine levels in the NAc by microdialysis. 
a Microdialysis schedule before and after DT treatment. b Sampling schedule after 
inserting the microdialysis probe. c Typical HPLC chromatograms of a dialysate and 
external adenosine standards. d Typical implantation site for the guide cannula and 
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location of the microdialysis probe in the NAc. Immunostaining for mCherry indicates 
the AAV-infected area in the NAc. Scale bar: 200 μm. e Extracellular adenosine levels 
normalized to baseline in the NAc of A2AR
WT NAc GFAP-mCherry (n=4), A2AR
WT NAc 
GFAP-DTR (n=5), and A2AR
KO NAc GFAP-DTR (n=4) mice on day 7 after treatment 
with 50 μg/kg DT. Significance was assessed by one-way ANOVA followed by the 
PLSD test. 
 
5. Discussion  
A recent study showed that chemogenetic or optogenetic activation of NAc core A2AR 
neurons projecting to the ventral pallidum strongly induces SWS, whereas 
chemogenetic inhibition of these neurons prevents sleep induction, but does not affect 
the homoeostatic sleep rebound (Oishi et al., 2017). We hypothesized that adenosine is 
a candidate molecule for activating NAc A2AR neurons. Where in the NAc adenosine 
is generated, however, remains unknown. Adenosine is not a neurotransmitter or a 
typical neuromodulator released from neurons, because it can be formed by various 
processes in all cell types (Ohana et al., 2001). Cytotoxic ablation of GFAP-positive 
cells, which are likely astrocytes, as well as a small number of neurons in the NAc led 
to a transient increase in SWS over several days in mice. Further analysis of the 
molecular mechanisms revealed that extracellular adenosine levels increased after 
ablation and the SWS increase was mediated by A2AR.  
Surprisingly, the number of astrocytes in the NAc core was also increased after GFAP-
positive cell ablation. The increase in the number of astrocytes may be due to 
astrogliosis, i.e., astrocyte migration or proliferation, after apoptotic destruction of 
astrocytes or neurons by DT (Aldskogius & Kozlova, 1998; Morimoto & Bonavida, 
1992). We suspect that the increase in extracellular adenosine is due to the increased 
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number of astrocytes. A role for astrocytes in sleep regulation has only recently started 
to emerge. Extracellular levels of adenosine and recovery sleep after sleep deprivation 
are reduced when the release of ATP is blocked by the transgenic expression of the 
dnSNARE protein in astrocytes (Chen & Scheller, 2001; Halassa et al., 2009; Pascual 
et al., 2005; Raingo et al., 2012) and astrocytic adenosine kinase is involved in 
regulating homeostatic sleep (Bjorness et al., 2016). Moreover, optogenetic stimulation 
of astrocytes in the posterior hypothalamus increases sleep (Pelluru et al., 2016).  
The possibility that activated microglia also contribute to the elevated adenosine levels 
cannot be excluded. Microglia are immune cells distributed throughout the brain, 
comprising 10% to 20% of the glial population (Ginhoux et al., 2013). Microglia in a 
phagocytic state are usually involved in the clearance of apoptotic cells (Lian et al., 
2016). The role of microglia in sleep regulation remains elusive. Some studies reported 
that microglia are activated after sleep deprivation (Huang et al., 2014; Wadhwa et al., 
2018; Wisor et al., 2011). Microglia activation is likely a consequence of sleep loss, 
however, rather than the cause of sleep rebound. Microglia are considered to be a major 
source of cytokines, but there is almost no evidence indicating that microglia can release 
adenosine (Hanisch, 2002; Smith et al., 2012). In contrast, adenosine has an important 
role in regulating microglia via adenosine receptors (Gyoneva et al., 2009; Luongo et 
al., 2014; Madeira et al., 2018; Orr et al., 2009). Future studies utilizing opto- or 
chemogenetic systems are needed to examine the ability of microglia to release 
adenosine and induce sleep. Moreover, cytokines have a known role in sleep/wake 
regulation, but the effects of cytokines released from microglia in the NAc on sleep 
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have never been investigated. The A2AR
KO NAc GFAP-DTR mice exhibited no increase 
in SWS after DTR-mediated ablation of astrocytes and neurons, suggesting that 
cytokines are not involved in the sleep phenotype. 
Moreover, the DTR was also expressed in neurons to some extent due to leakage of the 
GFAP promoter used in our viral vector and thus, it is possible that we also ablated a 
small number of neurons by DT administration. We do not consider this directly 
relevant, however, because the sleep/wake behavior of A2AR
KO mice is not affected by 
DTR-mediated ablation of astrocytes and neurons, and cytotoxic lesions of the NAc 
core or shell neurons induce wakefulness (Qiu et al., 2012). Neuronal ablation, however, 
may contribute to activate the astrocytes and microglia (Aldskogius and Kozlova, 1998). 
Strong reactivation of astrocytes and microglia in healthy mammalians is not a common 
phenomenon but usually it can be observed in brains with inflammation or injuries. 
Therefore, the cytotoxic ablation of astrocytes and neurons may mimic traumatic brain 
injury (TBI) which is often associated with sleep disorders. TBI patients experience 
high rates of insomnia (29%), hypersomnia (28%), and sleep apnea (25%) (Wickwire 
et al., 2016). For example, hypersomnia was observed in patients with thalamic 
astrogliosis and increased adenosine levels in the cerebral spinal fluid during an acute 
period after TBI (Hazra et al., 2014; Rowe et al., 2014; Zuzuárregui et al., 2018). An 
imbalance of neurotransmitters (e.g., GABA, glutamate and orexin) or increased 
cytokine production in the hypothalamus or brain stem after TBI, however, is believed 
to cause the sleep disturbance (Sandsmark et al., 2017). Although adenosine is known 
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to play an important role in neuroprotection after TBI (Lusardi, 2009), the involvement 
of adenosine, especially in the NAc, in TBI-related sleep disorders remains unclear. 
 
6. Conclusion 
Activation of A2AR neurons in the NAc core promotes SWS sleep and elevated 
adenosine levels in the NAc core increase SWS by acting on A2AR. Our findings 
provide the first evidence that adenosine is a strong candidate molecule for activating 
NAc core A2AR neurons to induce SWS. 
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